Skip to content

Allopurinol in the prevention of pre-procedural myocardial injury following angioplasty

Randomized trial of allopurinol in the prevention of pre-procedural myocardial injury in patients undergoing angioplasty

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201412088307N11
Enrollment
100
Registered
2017-07-04
Start date
2014-10-02
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart diseases patients. Ischaemic heart diseases

Interventions

Intervention 1: Control: In the control group, patients only will be given the standard treatment. Intervention 2: Intervention: In allopurinol group, all patients will be received totally 1200 mg bef
Treatment - Drugs
Intervention: In allopurinol group, all patients will be received totally 1200 mg before PCI plus the standard treatment.

Sponsors

Vice chancellor for research, Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Ischemic heart diseases patients; age 18-80; undergoing of angioplasty with stent insertion; filling of consent form. Exclusion Criteria: Elevation of CK-MB and cTnI before PCI; history of CABG during last three months; history of previous MI; renal dysfunction (creatinine above 2.5 mg/dl); unsuccessful PCI; acute MI; cardiogenic shock; dialysis; pregnancy; inability in filling and understanding of the consent form; unconsented patients; patients who want to discontinue the study at any time

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
CK-MB level. Timepoint: 12 hours Before, 8 and 24 hours after angioplasty. Method of measurement: ELISA.;CTnI level. Timepoint: Before, 8 and 24 hours after angioplasty. Method of measurement: ELISA.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Taher Entezari-Maleki

Tabriz University of Medical Sciences

tentezari@gmail.com+98 41 3339 2593

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026